Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Laboratorios Farmaceuticos Rovi, S.A.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Laboratorios Farmaceuticos Rovi, S.A.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: Laboratorios Farmaceuticos Rovi, S.A.
  • The company's enterprise value to sales, at 3.86 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.

Rating Financials

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.48B
BBB
1,010B
A
580B
BBB
402B -
AA
- -
330B
AA
281B
AAA
280B
A
197B
A
192B
A
156B
AA
Average 343.24B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ROVI Stock
  4. Ratings Laboratorios Farmaceuticos Rovi, S.A.
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!